Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mizuho Discusses Biogen (BIIB) Seizure Patient
December 9, 2016 2:15 PM ESTMizuho analyst Salim Syed discussed Biogen (NASDAQ: BIIB) Aducanumab's LTE seizure patient, which has the stock well off highs (+0.4%).
"On the seizure patient, we spoke to the company (they weren't willing to say much beyond the slide) ... this is a new... More
Biogen (BIIB) Shares Should Trade Higher on CTAD Data - BMO Capital
December 9, 2016 6:29 AM ESTBMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
UPDATE: Biogen (BIIB), Biotechs Gain Mid-Day
December 8, 2016 3:03 PM EST(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
